Mr. Rona brings over 15 years experience in originating, structuring and executing corporate transactions and financings. Most recently, Mr. Rona was Vice President of Corporate Development for Corgentech, Inc. following the merger between Corgentech and AlgoRx Pharmaceuticals in late 2005. Prior to the merger, Mr. Rona was the Chief Financial Officer of AlgoRx, and was responsible for the execution of the merger with Corgentech. Mr. Rona also led AlgoRx $65 million Series C financing in early 2004. Prior to joining AlgoRx in 2002, Mr. Rona was in the Investment Banking department at UBS Warburg. Mr. Rona has also served as the director of finance and corporate development at Antigenics, taking the Company public in early 2000. Mr. Rona started his career at Coopers & Lybrand where he spent seven years serving clients needs in accounting, tax and corporate finance. Mr. Rona received a B.S. in Accounting from Case Western Reserve University in 1990. |